MCM
CDTX

Manchester Capital Management’s Cidara Therapeutics CDTX Stock Holding History

Manchester Capital Management’s Portfolio CDTX Stock Details CDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-470
Closed -$12.6K – 1174
2024
Q4 		$12.6K Hold
470
– – ﹤0.01% 772
2024
Q3 		$5.05K Hold
470
– – ﹤0.01% 888
2024
Q2 		$5.61K Buy
+470
New +$6.43K ﹤0.01% 837

Other funds holding CDTX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Manchester Capital Management's CDTX Position: Q1 2025 in Review

Manchester Capital Management sold out of Cidara Therapeutics (CDTX) in Q1 2025, closing a stake of 470 shares — an estimated $12.6K sold.

Manchester Capital Management first reported a position in CDTX in Q2 2024 and held it in 3 quarters. The position peaked at $12.6K in Q4 2024. 46 funds tracked by Wall St. Rank hold CDTX as of Q1 2025.

  • Manchester Capital Management reported no remaining Cidara Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Manchester Capital Management sold 470 Cidara Therapeutics shares in Q1 2025, an estimated $12.6K.
  • Manchester Capital Management first reported a position in Cidara Therapeutics in Q2 2024 and held it in 3 quarters.
  • Manchester Capital Management's Cidara Therapeutics position peaked at $12.6K in Q4 2024.
  • 46 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q1 2025.

Based on Manchester Capital Management's 13F filing for Q1 2025, filed 9 May 2025.